SCHEMBL6165734

SCHEMBL6165734

CC(C)(C)OC(=O)Nc1cc(N2CCCC2)c(C#N)cc1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.53
MAPT P10636 8/20 0.53
HTT P42858 3/20 0.53
LMNA P02545 4/20 0.47
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 6/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
NPSR1 Q6W5P4 3/20 0.40
GAA P10253 2/20 0.40
ABCB1 P08183 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.40
TDP1 Q9NUW8 2/20 0.38
TP53 P04637 1/20 0.38
HPGD P15428 1/20 0.38
CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6167117 0.99 ALDH1A1 (0.55) ALDH1A1MAPTHTTLMNAKMT2A
SCHEMBL6437295 0.91 MAPT (0.42) ALDH1A1MAPTHTTLMNAKMT2A
SCHEMBL6437854 0.91 ALDH1A1 (0.46) ALDH1A1MAPTHTTLMNAKMT2A
SCHEMBL6167431 0.85 SMN1; SMN2 (0.46) ALDH1A1MAPTLMNAKMT2AMEN1
SCHEMBL7146607 0.84 MAPT (0.44) ALDH1A1MAPTHTTKMT2AMEN1
SCHEMBL6163733 0.84 MAPT (0.52) ALDH1A1MAPTHTTLMNAKMT2A
SCHEMBL6164728 0.84 MAPT (0.54) ALDH1A1MAPTHTTLMNACYP1A2
SCHEMBL6164183 0.83 MAPT (0.53) ALDH1A1MAPTHTTLMNAKMT2A
SCHEMBL6165021 0.83 NPSR1 (0.40) ALDH1A1MAPTHTTLMNAKMT2A
SCHEMBL5557531 0.83 SERPINE1 (0.44) ALDH1A1MAPTLMNASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379511-B1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II HOFFMANN LA ROCHE (CH) 2005-07-20 EP disclosed
EP-1379511-A1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2004-01-14 EP disclosed
US-6544985-B2 For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits HOFFMAN-LA ROCHE INC. 2003-04-08 US disclosed
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) 2002-12-19 US disclosed
WO-2002083652-A1 DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives CYP1B1, GRIN2B, BDKRB1 ALDH1A1 316/4885MAPT 1155/4885HTT 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.